| Symbol | CPRX |
|---|---|
| Name | CATALYST PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 355 ALHAMBRA CIRCLE,SUITE 801, CORAL GABLES, Florida, 33134, United States |
| Telephone | +1 305 - 420-3200 |
| Fax | — |
| — | |
| Website | https://www.catalystpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001369568 |
| Description | Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. Additional info from NASDAQ: |
2026-04-30 17:32
New Form 10-K/A - CATALYST PHARMACEUTICALS, INC. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-197490 <b>Size:</b> 1 MB
Read more
2026-04-28 12:03
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Read more
2026-03-06 13:03
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Read more
2026-02-25 21:23
(30% Negative) Catalyst Pharmaceuticals Inc. (CPRX) Reports Q1 2026 Financial Results
Read more
2026-02-25 21:07
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Read more
2026-02-24 13:03
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
Read more
2026-02-19 22:04
Russo Gregg 🟡 adjusted position in 211 shares (1 derivative) of CATALYST PHARMACEUTICALS, INC. (CPRX) Transaction Date: Feb 17, 2026 | Filing ID: 000044
Read more
2026-01-12 13:03
(90% Positive) Catalyst Pharmaceuticals Inc. (CPRX) Announces Business Combination
Read more
2026-01-08 13:03
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of Americas Most Successful Small-Cap Companies
Read more
2026-01-06 22:00
Kalb Michael Wayne 🟡 adjusted position in 2.1K shares (1 derivative) of CATALYST PHARMACEUTICALS, INC. (CPRX) Transaction Date: Jan 05, 2026 | Filing ID: 000022
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02189720 | Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndr… | — | Congenital Myasthenic Syndrome | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT03062631 | Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia | — | Congenital Myasthenic Syndrome | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06564974 | Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients… | — | Duchenne Muscular Dystrophy | Recruiting | 2024-09-25 | 2032-02-01 | ClinicalTrials.gov |
| NCT06106451 | Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study) | Na | Aortic Valve Disease | Completed | 2024-01-29 | 2025-11-03 | ClinicalTrials.gov |
| NCT05796570 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Trans… | Phase2 | Acute Myeloid Leukemia | Recruiting | 2023-04-19 | 2029-09-01 | ClinicalTrials.gov |
| NCT05556824 | Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therap… | Phase2 | Gastroesophageal Reflux | Active_Not_Recruiting | 2023-03-03 | 2026-05-01 | ClinicalTrials.gov |
| NCT05569551 | Umbilical Cord Care in Term Neonates: The Role of Wondaleaf Adhesive Pouch (WLA… | Na | Umbilical Cord Infection | Completed | 2022-11-15 | 2023-09-16 | ClinicalTrials.gov |
| NCT04968405 | Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty | Na | Osteoarthritis Shoulder | Completed | 2022-07-22 | 2026-02-01 | ClinicalTrials.gov |
| NCT05094401 | Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes | Phase3 | Type2 Diabetes | Terminated | 2021-10-04 | 2023-04-01 | ClinicalTrials.gov |
| NCT05095623 | A Natural History Study to Assess the Clinical Outcomes of Patients With Comple… | — | Recurrent Bacterial Infection, Autoimmune Disorder | Terminated | 2021-08-31 | 2022-02-10 | ClinicalTrials.gov |
| NCT05072912 | Screening Study to Identify Patients With Complement Factor I Deficiencies | — | Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency | Terminated | 2021-07-21 | 2021-11-23 | ClinicalTrials.gov |
| NCT04920916 | Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients | Phase2 | COVID-19 | Completed | 2021-05-25 | 2023-04-18 | ClinicalTrials.gov |
| NCT04548791 | Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With … | Phase1 | Factor VII Deficiency | Terminated | 2021-05-17 | 2021-12-03 | ClinicalTrials.gov |
| NCT04489537 | Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With … | Phase3 | Hemophilia A With Inhibitor | Terminated | 2021-05-04 | 2021-12-01 | ClinicalTrials.gov |
| NCT04072237 | Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult… | Phase1 | Hemophilia A | Completed | 2019-09-24 | 2020-06-17 | ClinicalTrials.gov |
| NCT03995784 | Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With H… | Phase2 | Hemophilia B | Completed | 2019-06-18 | 2020-04-30 | ClinicalTrials.gov |
| NCT03819660 | Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 | Phase2 | Spinal Muscular Atrophy Type 3 | Terminated | 2019-03-07 | 2021-09-13 | ClinicalTrials.gov |
| NCT03781479 | Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy… | Phase2 | Muscular Atrophy, Spinal | Completed | 2019-01-21 | 2020-07-23 | ClinicalTrials.gov |
| NCT03579966 | Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific T… | Phase3 | Myasthenia Gravis, MuSK | Terminated | 2018-06-11 | 2022-08-05 | ClinicalTrials.gov |
| NCT03304054 | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG | Phase3 | Myasthenia Gravis, Generalized | Completed | 2018-04-18 | 2020-03-15 | ClinicalTrials.gov |
| NCT03407651 | Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult … | Phase2 | Hemophilia A With Inhibitor | Completed | 2017-12-18 | 2019-04-13 | ClinicalTrials.gov |
| NCT03324594 | A Pilot Functional Performances Study of Two Synthetic Male Condom | Na | Functional Performance | Completed | 2017-11-01 | 2018-03-31 | ClinicalTrials.gov |
| NCT03186677 | Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d i… | Phase1 | Hemophilia B | Completed | 2017-06-03 | 2019-02-22 | ClinicalTrials.gov |
| NCT02970162 | Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton … | Phase3 | Lambert-Eaton Myasthenic Syndrome | Completed | 2016-11-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02857972 | Proof Of Concept Menstrual Hygiene Product-Wondaleaf® | Na | Other Menstruation Disorders | Completed | 2016-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02562066 | Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes | Phase3 | Myasthenic Syndromes, Congenital | Completed | 2016-01-01 | 2019-10-01 | ClinicalTrials.gov |
| NCT02660645 | Blue Light Cystoscopy With Cysview® Registry | — | Bladder Cancer | Recruiting | 2014-04-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT01493596 | A Safety, Tolerability and Pharmacokinetic Study of CPP-115 | Phase1 | Cocaine Dependency | Completed | 2011-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01439971 | Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Fact… | Phase1 | Hemophilia A | Completed | 2011-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01377922 | A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myast… | Phase3 | Lambert Eaton Myasthenic Syndrome | Completed | 2011-06-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01281202 | Vigabatrin for the Treatment of Cocaine Dependency | Phase2 | Cocaine Addiction | Completed | 2011-01-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00830531 | Pilot Study of Bumetanide for Newborn Seizures | Phase1 | Seizures | Completed | 2010-01-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT00730522 | Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence | Phase2 | Methamphetamine Dependence | Terminated | 2008-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00611130 | Vigabatrin for Treatment of Cocaine Dependence | Phase2 | Cocaine Dependence | Completed | 2008-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00527683 | Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence | Phase2 | Cocaine Dependence | Completed | 2007-04-01 | 2007-11-01 | ClinicalTrials.gov |
Total clinical trials: 35
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Cocaine Dependency | COMPLETED | NCT01493596 |
| CPP-115 | Other | Phase PHASE1 | Cocaine Dependency | COMPLETED | NCT01493596 |
| Coagulation Factor VIIa variant | Other | Phase PHASE1 | Factor VII Deficiency | TERMINATED | NCT04548791 |
| Matching Placebo | Other | Phase PHASE2 | Cocaine Addiction | COMPLETED | NCT01281202 |
| Vigabatrin | Other | Phase PHASE2 | Cocaine Addiction | COMPLETED | NCT01281202 |
| Wondaleaf® | Other | Approved | Other Menstruation Disorders | COMPLETED | NCT02857972 |
| Wondaleaf® | Other | Approved | Other Menstruation Disorders | COMPLETED | NCT02857972 |
| PF-05280602 | Other | Phase PHASE1 | Hemophilia A | COMPLETED | NCT01439971 |
| Placebo | Other | Phase PHASE3 | Lambert Eaton Myasthenic Syndrome | COMPLETED | NCT01377922 |
| Amifampridine Phosphate | Other | Phase PHASE3 | Lambert Eaton Myasthenic Syndrome | COMPLETED | NCT01377922 |
| (1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator) | Other | Approved | Functional Performance | COMPLETED | NCT03324594 |
| (1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator) | Other | Approved | Functional Performance | COMPLETED | NCT03324594 |
| (1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator) | Other | Approved | Functional Performance | COMPLETED | NCT03324594 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Lambert-Eaton Myasthenic Syndrome | COMPLETED | NCT02970162 |
| Amifampridine Phosphate | Other | Phase PHASE3 | Lambert-Eaton Myasthenic Syndrome | COMPLETED | NCT02970162 |
| BeneFIX | Other | Phase PHASE1 | Hemophilia B | COMPLETED | NCT03186677 |
| ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg | Other | Phase PHASE1 | Hemophilia B | COMPLETED | NCT03186677 |
| Normal Saline as Placebo | Other | Phase PHASE1 | Seizures | COMPLETED | NCT00830531 |
| Bumetanide | Other | Phase PHASE1 | Seizures | COMPLETED | NCT00830531 |
| Normal Saline as Placebo | Other | Phase PHASE1 | Seizures | COMPLETED | NCT00830531 |
| Bumetanide | Other | Phase PHASE1 | Seizures | COMPLETED | NCT00830531 |
| Placebo | Other | Phase PHASE3 | Myasthenic Syndromes, Congenital | COMPLETED | NCT02562066 |
| amifampridine phosphate | Other | Phase PHASE3 | Myasthenic Syndromes, Congenital | COMPLETED | NCT02562066 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Muscular Atrophy, Spinal | COMPLETED | NCT03781479 |
| Amifampridine Phosphate | Other | Phase PHASE2 | Muscular Atrophy, Spinal | COMPLETED | NCT03781479 |
| Coagulation Factor IX variant | Other | Phase PHASE2 | Hemophilia B | COMPLETED | NCT03995784 |
| MarzAA (marzeptacog alfa [activated]) | Other | Phase PHASE1 | Hemophilia A | COMPLETED | NCT04072237 |
| Coagulation Factor VIIa variant | Other | Phase PHASE2 | Hemophilia A With Inhibitor | COMPLETED | NCT03407651 |
| MarzAA | Other | Phase PHASE3 | Hemophilia A With Inhibitor | TERMINATED | NCT04489537 |
| Natural History Observation | Other | Preclinical | Recurrent Bacterial Infection, Autoimmune Disorder | TERMINATED | NCT05095623 |
| 3,4-Diaminopyridine | Other | Preclinical | Congenital Myasthenic Syndrome | NO_LONGER_AVAILABLE | NCT03062631 |
| BT-001 | Other | Phase PHASE3 | Type2 Diabetes | TERMINATED | NCT05094401 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04920916 |
| Dupilumab | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04920916 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04920916 |
| Dupilumab | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04920916 |
| Amifampridine Phosphate 10 MG Oral Tablet | Other | Phase PHASE2 | Spinal Muscular Atrophy Type 3 | TERMINATED | NCT03819660 |
| Adhesive pouch | Other | Approved | Umbilical Cord Infection | COMPLETED | NCT05569551 |
| Adhesive pouch | Other | Approved | Umbilical Cord Infection | COMPLETED | NCT05569551 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Myasthenia Gravis, Generalized | COMPLETED | NCT03304054 |
| Amifampridine Phosphate | Other | Phase PHASE3 | Myasthenia Gravis, Generalized | COMPLETED | NCT03304054 |
| Amifampridine Phosphate | Other | Phase PHASE3 | Myasthenia Gravis, MuSK | TERMINATED | NCT03579966 |
| Amifampridine Phosphate | Other | Preclinical | Congenital Myasthenic Syndrome | APPROVED_FOR_MARKETING | NCT02189720 |
| Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux | ACTIVE_NOT_RECRUITING | NCT05556824 |
| MHS-1031 | Other | Phase PHASE2 | Gastroesophageal Reflux | ACTIVE_NOT_RECRUITING | NCT05556824 |
| Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux | ACTIVE_NOT_RECRUITING | NCT05556824 |
| MHS-1031 | Other | Phase PHASE2 | Gastroesophageal Reflux | ACTIVE_NOT_RECRUITING | NCT05556824 |
| Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Other | Preclinical | Bladder Cancer | RECRUITING | NCT02660645 |
| Hexaminolevulinate hydrochloride (HCL) | Other | Preclinical | Bladder Cancer | RECRUITING | NCT02660645 |
| Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Other | Preclinical | Bladder Cancer | RECRUITING | NCT02660645 |
| Hexaminolevulinate hydrochloride (HCL) | Other | Preclinical | Bladder Cancer | RECRUITING | NCT02660645 |
| Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Other | Preclinical | Bladder Cancer | RECRUITING | NCT02660645 |
| Hexaminolevulinate hydrochloride (HCL) | Other | Preclinical | Bladder Cancer | RECRUITING | NCT02660645 |
| Vamorolone | Other | Preclinical | Duchenne Muscular Dystrophy | RECRUITING | NCT06564974 |
| Home-Based Activity Program plus Motivational Interviewing Intervention | Other | Approved | Aortic Valve Disease | COMPLETED | NCT06106451 |
| Motivational Interviewing Intervention | Other | Approved | Aortic Valve Disease | COMPLETED | NCT06106451 |
| Standard of Care plus Enhanced Patient Education | Other | Approved | Aortic Valve Disease | COMPLETED | NCT06106451 |
| Filgrastim | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05796570 |
| Decitabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05796570 |
| Filgrastim | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05796570 |
| Decitabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05796570 |
| Catalyst CSR Total Shoulder System | Other | Approved | Osteoarthritis Shoulder | COMPLETED | NCT04968405 |
| Catalyst CSR Total Shoulder System | Other | Approved | Osteoarthritis Shoulder | COMPLETED | NCT04968405 |
| Vamorolone | DRUG | Preclinical | Duchenne Muscular Dystrophy | RECRUITING | NCT06564974 |
| Natural History Observation | OTHER | Preclinical | Recurrent Bacterial Infection, Autoimmune Disorder | TERMINATED | NCT05095623 |
| BT-001 | DEVICE | Phase PHASE3 | Type2 Diabetes | TERMINATED | NCT05094401 |
| MarzAA | BIOLOGICAL | Phase PHASE3 | Hemophilia A With Inhibitor | TERMINATED | NCT04489537 |
| MarzAA (marzeptacog alfa [activated]) | BIOLOGICAL | Phase PHASE1 | Hemophilia A | COMPLETED | NCT04072237 |
| Coagulation Factor IX variant | BIOLOGICAL | Phase PHASE2 | Hemophilia B | COMPLETED | NCT03995784 |
| Amifampridine Phosphate 10 MG Oral Tablet | DRUG | Phase PHASE2 | Spinal Muscular Atrophy Type 3 | TERMINATED | NCT03819660 |
| Coagulation Factor VIIa variant | BIOLOGICAL | Phase PHASE1 | Factor VII Deficiency | TERMINATED | NCT04548791 |
| BeneFIX | BIOLOGICAL | Phase PHASE1 | Hemophilia B | COMPLETED | NCT03186677 |
| ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg | BIOLOGICAL | Phase PHASE1 | Hemophilia B | COMPLETED | NCT03186677 |
| 3,4-Diaminopyridine | DRUG | Preclinical | Congenital Myasthenic Syndrome | NO_LONGER_AVAILABLE | NCT03062631 |
| Placebo Oral Tablet | DRUG | Phase PHASE2 | Muscular Atrophy, Spinal | COMPLETED | NCT03781479 |
| amifampridine phosphate | DRUG | Phase PHASE3 | Myasthenic Syndromes, Congenital | COMPLETED | NCT02562066 |
| CPP-115 | DRUG | Phase PHASE1 | Cocaine Dependency | COMPLETED | NCT01493596 |
| PF-05280602 | BIOLOGICAL | Phase PHASE1 | Hemophilia A | COMPLETED | NCT01439971 |
| Placebo | DRUG | Phase PHASE3 | Myasthenic Syndromes, Congenital | COMPLETED | NCT02562066 |
| Amifampridine Phosphate | DRUG | Phase PHASE2 | Muscular Atrophy, Spinal | COMPLETED | NCT03781479 |
| Vigabatrin | DRUG | Phase PHASE2 | Cocaine Addiction | COMPLETED | NCT01281202 |
| Matching Placebo | DRUG | Phase PHASE2 | Cocaine Addiction | COMPLETED | NCT01281202 |
| CPP-109 vigabatrin | DRUG | Phase PHASE2 | Methamphetamine Dependence | TERMINATED | NCT00730522 |
| placebo | DRUG | Phase PHASE2 | Cocaine Dependence | COMPLETED | NCT00611130 |
| vigabatrin | DRUG | Phase PHASE2 | Cocaine Dependence | COMPLETED | NCT00611130 |
Total products: 85